Shots:

• The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with r/r MM 96 centers in 24 countries
• The study resulted in meeting al 1EPs with safe and effective results
• Isatuximab is used for targeting CD38- involved in apoptosis and immunomodulatory activity- has received ODD from the US FDA & EU for r/r multiple myeloma and is evaluated in other hematologic malignancies and solid tumors

  Ref: Sanofi | Image:  Biospace